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Abstract 
Chlamydia trachomatis is a bacterial pathogen that is the leading cause of bacterial “Sexual 
Transmitted Disease” (STD) in developing countries. Most often the infection is 
asymptomatic. However, if the infection remains untreated, it often results in pelvic 
inflammatory disease (PID), ectopic pregnancy, chronic pelvic pain in women, urethritis and 
epididymitis in men or infant pneumonia. The infection can easily be treated with antibiotics, 
but in most cases damage is already done before the bacterium is noticed. Immunization is 
considered to be the best approach to reduce C. trachomatis infections. However, so far no 
vaccine is available.  
In this study, plasmid DNA (pWRG7079::MOMP) expressing the major outer membrane 
protein of a human Chlamydia trachomatis serovar E strain was tested for the ability to induce 
an immune response and protect against experimental genital infection with the same serovar. 
The vaccine was tested in pigs, as they are genetically, physiologically and immunologically 
related to humans and suitable for studying C. trachomatis infection of the genital system. To 
increase the immune response, GM-CSF and LTa + LTb were used as adjuvants. GM-CSF 
was administered seven days before immunization, while the other adjuvants were 
administered together with the vaccine. Ten pigs were randomly divided into two groups. One 
group received an intravaginal primo-vaccination and a booster of 500 µg 
pWRG7079::MOMP, while the other group received the placebo vaccine pWRG7079. All 
animals were challenged intravaginally with 10
8
 TCID50 of C. trachomatis serovar E. Pigs 
immunized with the DNA vaccine showed significantly less macroscopic lesions, vaginal 
excretion and chlamydial replication in the genital tract, as compared to placebo-vaccinated 
controls. A clear relationship could be detected between high stimulation indices in the 
lymphocyte proliferation assays and better protection. However, the infection could not be 
completely cleared.  
 
